Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (289)	1/7/1999 9:15:00 PM
From: Epicenter	Read Replies (1) \| Respond to of 656

There are many kinases (some estimate 1000). Coming up with a kinase inhibitor that is specific and therefore safe in a chronic administration setting is not trivial. Personally, I would not put such investment on a high priority (although there are lots of other knowledgeable scientists who do!!). Epicenter

To: Mike McFarland who wrote (289)	1/12/1999 6:14:00 AM
From: Henry Niman	Respond to of 656

Today's WSJ reviews earnings for the larger profitable Biotechs. New products of course played a major role in the increased earnings of 4Q. The companies and products covered include AMGN (NESP), BGEN (Avonex), CHIR (Proleukin), CNTO (Reopro/Remicade), GNE (Herceptin), GENZ (Cerezyme/Ceredase), IMNX (Enbrel), AGPH (Viracept). Details linked to the Biotech Boom table (which also has a list of Biotechs presenting at this week's H&Q Healthcare Conference) at biocognizance.com